PMID- 26696788
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151223
LR  - 20201001
IS  - 1507-1367 (Print)
IS  - 2083-4640 (Electronic)
IS  - 1507-1367 (Linking)
VI  - 20
IP  - 6
DP  - 2015 Nov-Dec
TI  - Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients 
      feasible and effective?
PG  - 472-83
LID - 10.1016/j.rpor.2014.10.004 [doi]
AB  - OBJECTIVES: To review the available data about stereotactic body-radiotherapy 
      (SBRT) for oligometastatic lymph node cancer recurrence. METHODS: The inclusion 
      criteria for this study were as follows: Medline search for the (1) English 
      language (2) full paper (abstracts were excluded) on (3) adult oligometastatic 
      solid cancer recurrence limited to lymph node that underwent SBRT (4) outcome 
      data available and (5) published up to the 30th April 2014. RESULTS: 38 papers 
      fulfilling the inclusion criteria have been found: 7 review articles and 31 
      patient series (20 and 11 retrospective and prospective studies, respectively) 
      including between 1 and 69 patients (636 lymph nodes). Twelve articles reported 
      only lymph node SBRT while in 19 - all types of SBRT including lymph node SBRT 
      were presented. Two-year local control, 4-year progression free survival and 
      overall survival was of up to 100%, 30% and 50%, respectively. The progression 
      was mainly out-field (10-30% of patients had a recurrence in another lymph 
      node/nodes). The toxicity was low with mainly mild acute events and single grade 
      3-4 late events. When compared to SBRT for any oligometastatic cancer, SBRT for 
      lymph node recurrence carried better prognosis and showed lower toxicity. 
      CONCLUSIONS: SBRT is a feasible approach for oligometastatic lymph node 
      recurrence, offering excellent in-field tumor control with low toxicity profile. 
      The potential abscopal effect has been hypothesized as a basis of these findings. 
      Future studies are warranted to identify the patients that benefit most from this 
      treatment. The optimal combination with systemic treatment should also be 
      defined.
FAU - Jereczek-Fossa, Barbara Alicja
AU  - Jereczek-Fossa BA
AD  - Department of Radiotherapy of the European Institute of Oncology, Milan, Italy ; 
      University of Milan, Milan, Italy.
FAU - Ronchi, Sara
AU  - Ronchi S
AD  - Department of Radiotherapy of the European Institute of Oncology, Milan, Italy ; 
      Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy ; University of 
      Milan, Milan, Italy.
FAU - Orecchia, Roberto
AU  - Orecchia R
AD  - Department of Radiotherapy of the European Institute of Oncology, Milan, Italy ; 
      Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy ; University of 
      Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20141107
PL  - Poland
TA  - Rep Pract Oncol Radiother
JT  - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer 
      Center in Poznan and Polish Society of Radiation Oncology
JID - 100885761
PMC - PMC4661354
OTO - NOTNLM
OT  - Lymph nodes
OT  - Oligometastatic cancer
OT  - Recurrent cancer
OT  - Stereotactic body radiotherapy
EDAT- 2015/12/24 06:00
MHDA- 2015/12/24 06:01
PMCR- 2016/11/01
CRDT- 2015/12/24 06:00
PHST- 2014/06/04 00:00 [received]
PHST- 2014/08/27 00:00 [revised]
PHST- 2014/10/10 00:00 [accepted]
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2015/12/24 06:01 [medline]
PHST- 2016/11/01 00:00 [pmc-release]
AID - S1507-1367(14)00169-2 [pii]
AID - 10.1016/j.rpor.2014.10.004 [doi]
PST - ppublish
SO  - Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):472-83. doi: 
      10.1016/j.rpor.2014.10.004. Epub 2014 Nov 7.